The U.S. FDA has approved intravenous fosfomycin (Contepo) for treating adults with complicated urinary tract infections (cUTI), including acute pyelonephritis , caused by susceptible E. coli and Klebsiella pneumoniae , as announced by Meitheal Pharmaceuticals.

CONTEPO, an intravenous (IV) antibiotic that is an injectable epoxide and sole antibiotic class member, has demonstrated activity against gram-negative bacteria including Escherichia coli and Klebsiella pneumoniae that cause cUTIs.1,2 It has no known cross-resistance to other antibiotic classes.3,4 Targeting bacteria’s cell wall at an earlier stage than β-lactam antibiotics, CONTEPO’s unique mechanism of action inhibits the first committed step in bacterial cell wall synthesis, eliminating all downstream signaling that is v

See Full Page